Kathleen Sereda Glaub Net Worth

The estimated Net Worth of Kathleen Sereda Glaub is at least $960 Thousand dollars as of 25 September 2018. Kathleen Glaub owns over 14,492 units of Codexis stock worth over $173,448 and over the last 10 years Kathleen sold CDXS stock worth over $786,771.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Kathleen Glaub CDXS stock SEC Form 4 insiders trading

Kathleen has made over 3 trades of the Codexis stock since 2018, according to the Form 4 filled with the SEC. Most recently Kathleen sold 14,492 units of CDXS stock worth $272,884 on 25 September 2018.

The largest trade Kathleen's ever made was selling 20,094 units of Codexis stock on 19 September 2018 worth over $360,486. On average, Kathleen trades about 4,954 units every 8 days since 2014. As of 25 September 2018 Kathleen still owns at least 63,534 units of Codexis stock.

You can see the complete history of Kathleen Glaub stock trades at the bottom of the page.

What's Kathleen Glaub's mailing address?

Kathleen's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Codexis

Over the last 15 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000..., and John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.

What does Codexis do?

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop

Complete history of Kathleen Glaub stock trades at Codexis

Codexis executives and stock owners

Codexis executives and other stock owners filed with the SEC include:

• John Nicols,
  President, Chief Executive Officer, Director
• John J. Nicols,
  Pres, CEO & Director
• Ross Taylor Jr., M.B.A.,
  Sr. VP & CFO
• Ross Taylor,
  Chief Financial Officer, Senior Vice President
• Bernard Kelley,
  Independent Chairman of the Board
• Byron Dorgan,
  Independent Director
• Pam Cheng,
  Independent Director
• David Smith,
  Independent Director
• Patrick Yang,
  Independent Director
• Dennis Wolf,
  Independent Director
• Thomas Baruch,
  Independent Director
• Jennifer Aaker,
  Independent Director
• Karen Frechou-Armijo,
  Sr. VP & Head of HR
• Asli Aras Ph.D.,
  VP of Corp. Devel.
• Dr. Davinder Singh Brar,
  Special Advisor to the Board
• Prof. Gerhard N. Mayr,
  Special Advisor to the Board
• Robert Sato M.B.A., Ph.D.,
  Sr. VP of Pharmaceutical Devel., Quality & Regulatory
• Dr. Stefan Lutz Ph.D.,
  Sr. VP of Research
• Rob Wilson Ph.D.,
  Sr. VP & GM of Performance Enzymes
• Dr. Gjalt Huisman Ph.D.,
  Sr. VP of Strategic Devel. & GM of Biotherapeutics
• Dr. Karl A. Schoene Ph.D.,
  Sr. VP of Devel. & Operations
• Kathleen Sereda Glaub,
  Director
• Gordon Sangster,
  SVP & Chief Financial Officer
• James Lalonde,
  SVP, R&D
• Ventures Vii, Llc Vivo Vent...,
  
• Douglas T. Sheehy,
  SVP, Gen Counsel and Sec.
• Sriram Ryali,
  Chief Financial Officer
• Ventures Fund Vii, L.P.Vivo...,
  
• David D O'toole,
  SVP & Chief Financial Officer
• Alexander Karsner,
  Director
• Matthew Tobin,
  SVP, Research & Development
• David L. Anton,
  SVP, Research and Development
• Ventures Life Sciences 2000...,
  
• James R Sulat,
  Director
• Mun Yew Wong,
  Director
• Brazil Holding B.V. Shell,
  10% owner
• Bruce A Pasternack,
  Director
• Robert J Lawson,
  SVP and CFO
• Brian Paul Dowd,
  Interim CFO
• Inc Maxygen,
  10% owner
• Peter M Strumph,
  Interim President and CEO
• Joseph J. Sarret,
  CBO, President Pharmaceuticals
• Peter Seufer Wasserthal,
  SVP, Pharmaceuticals
• Enterprises Llc Royal Dutch...,
  
• Alan Shaw,
  President and CEO
• Enterprises Llc Equilon,
  10% owner
• Participacoes Ltda.Royal Du...,
  
• Sciences Investment Fund Pt...,
  
• Esther Martinborough,
  
• H Stewart Parker,
  
• Rahul Singhvi,
  
• Alison Moore,
  
• Margaret Nell Fitzgerald,
  See Remarks
• Stephen George Dilly,
  See Remarks
• Kevin Norrett,
  Chief Operating Officer